spec sheet11 rows
Tetrahydrocannabivarin (THCV) is a naturally occurring, minor phytocannabinoid found in Cannabis sativa and the propyl homologue of delta-9-tetrahydrocannabinol (THC), differing only in a shortened three-carbon side chain [1][2]. It is pharmacologically distinct from THC: at low doses it behaves as a cannabinoid CB1 receptor antagonist that tends to suppress appetite, while at higher doses it can act as a CB1 agonist, and it is separately a high-affinity partial agonist at CB2 receptors [1][3]. Preclinical work and a small human trial point to benefits in glycaemic control, energy metabolism, neuroprotection and neuroinflammation, which has fuelled its reputation as a metabolically favourable, non-appetite-stimulating cannabinoid [4][5][6].
- Suppresses appetite rather than stimulating it
- Improves glycaemic control and insulin sensitivity
- Increases energy expenditure in animal models
- Anti-inflammatory and neuroprotective via CB2 agonism
- Non-intoxicating at low, CB1-antagonist doses
- At high doses it can shift to CB1 agonism and produce THC-like central effects.
- May lower blood glucose and appetite in ways that compound diabetes medication or unwanted weight loss.
Overview
Tetrahydrocannabivarin, commonly abbreviated THCV or THC-V, is a non-nitrogenous phytocannabinoid produced by Cannabis sativa and one of the more than one hundred cannabinoids identified in the plant. Structurally it is the propyl analogue of delta-9-tetrahydrocannabinol; where THC carries a five-carbon (pentyl) side chain on its aromatic ring, THCV carries a three-carbon (propyl) chain. This two-carbon difference is the single most important fact about the molecule, because it substantially changes how the compound engages cannabinoid receptors and therefore its behavioural and metabolic profile relative to THC [1][2].
The shortened side chain arises from a distinct biosynthetic branch. Rather than being built from hexanoyl-CoA like THC, THCV originates from divarinolic acid and cannabigerovarinic acid (CBGVA), the varinic (propyl) counterparts of the acids that feed conventional THC biosynthesis. Plants then produce tetrahydrocannabivarinic acid (THCVA), which decarboxylates on heating or ageing to yield neutral THCV. The molecular formula is C19H26O2 with a molar mass near 286.4 g/mol [2].
THCV is typically present only in small quantities in most drug-type and hemp cannabis, but certain landrace sativa populations, notably some from central and southern Africa and parts of central and south Asia, can accumulate comparatively high concentrations. This uneven distribution has made THCV a target for selective breeding and for extraction into isolates and formulated products. In pharmacological research the synthetic reference material has been designated O-4394 [1][2].
Legally, THCV occupies an ambiguous position that varies by jurisdiction. It is not the primary intoxicant that most cannabis regulation targets, and material sourced from low-THC hemp is often marketed in that context; however, its close structural relationship to THC means it can fall under controlled-substance or analogue provisions in some countries, and its status should be checked locally rather than assumed [1][4].
- THCV is the propyl twin of THC: it carries a three-carbon side chain instead of THC's five-carbon chain, and that one structural tweak is enough to flip it from an appetite stimulant into an appetite suppressant [1][5].
- It has an opposite personality at different doses; at low doses THCV blocks the CB1 receptor and curbs hunger, but at higher doses it can switch to activating CB1 and partially substitute for THC in animals trained to recognise it [3][10].
- In mice, THCV did not just make animals eat less; it actually raised their energy expenditure and improved insulin sensitivity, and in a human pilot trial it lowered fasting blood glucose and improved pancreatic beta-cell function in type 2 diabetes [4][6].
- Unlike the failed anti-obesity drug rimonabant, THCV blocks CB1 without the inverse-agonist signature that causes nausea, and it may even have anti-nausea potential of its own [8][9].
Mechanism
The defining feature of THCV pharmacology is a dose-dependent, and often paradoxical, relationship with the CB1 cannabinoid receptor. In vitro and in isolated tissues THCV is a high-affinity CB1 that acts as a potent of conventional CB1 agonists; radioligand and functional assays place its CB1 binding affinity in the high-nanomolar range and show that it can competitively block -induced signalling. In mouse cerebellar and piriform membranes, THCV antagonised WIN55,212-2-stimulated [35S]GTPgammaS binding with potency comparable in kind, if not magnitude, to the reference CB1 antagonist AM251 [3][7]. Importantly, a systematic review comparing THCV and cannabidiol concluded that THCV is not a rimonabant-like inverse in the way early work implied; behavioural assays found that, unlike the CB1 inverse agonists rimonabant and AM251, THCV did not produce the nausea-like conditioned gaping that is the signature of CB1 inverse agonism, positioning it closer to a neutral in vivo [8][9].
That behaviour, however, reverses with dose. At higher exposures THCV can behave as a CB1 in vivo, and in a rat drug-discrimination model trained to recognise THC, THCV produced an inverted-U substitution curve: it partially substituted for THC around 3 mg/kg yet reversed THC-appropriate responding at 6 mg/kg, consistent with a partial CB1 agonist whose net effect flips depending on receptor occupancy and endocannabinoid tone [10]. This biphasic CB1 story is the mechanistic root of THCV's most publicised property. By blocking CB1 at low doses, THCV opposes the appetite-stimulating, orexigenic signalling that CB1 agonists such as THC drive, which is why THCV suppresses food intake rather than provoking hunger [5].
Beyond CB1, THCV is a genuine high-affinity partial at the CB2 receptor, a profile that separates it from both THC and cannabidiol. CB2 activation is implicated in dampening inflammatory and immune signalling, and this CB2 agonism is thought to underpin much of THCV's anti-inflammatory and neuroprotective activity in disease models [1]. THCV also engages non-cannabinoid targets: it can enhance activation of receptors, and part of its antipsychotic-like activity in phencyclidine-treated rats was blocked by a 5-HT1A , indicating a serotonergic contribution to its central effects [11].
The metabolic actions of THCV are among its most compelling and best-supported. In dietary-induced and genetically obese (ob/ob) mice, THCV did not simply reduce feeding; it increased energy expenditure and improved sensitivity, lowering plasma glucose and insulin and reducing hepatic triglyceride accumulation, effects consistent with, but not fully explained by, CB1 antagonism [4]. These preclinical findings were partially borne out in humans: in a randomised, double-blind, placebo-controlled pilot study in people with non--treated type 2 diabetes, 5 mg twice-daily THCV significantly reduced fasting plasma glucose and improved pancreatic beta-cell function, adiponectin and apolipoprotein A relative to placebo, and was well tolerated [6].
Finally, THCV shows neurologically relevant activity through combined mechanisms. It exerted antiepileptiform and anticonvulsant effects in rat piriform slices and in a pentylenetetrazole seizure model in a manner consistent with CB1-mediated action [12]. In Parkinson's disease models its antioxidant properties together with CB1 antagonism and CB2 agonism reduced motor inhibition and protected dopaminergic neurons, and a related propyl-cannabinoid approach attenuated L-DOPA-induced dyskinesia, illustrating how THCV's multi-target profile can be leveraged in movement disorders [11][12].
receptor fingerprint
CB1 receptorneutral antagonist (low dose) / partial agonist (high dose)
CB2 receptorhigh-affinity partial agonist
Energy metabolism / sensitivityimproves glucose handling and energy expenditure
Appetite / food intakehypophagic (reduces food intake)
receptorpositive modulator / agonist-enhancer
Dopaminergic neurons (antioxidant / neuroprotective)neuroprotective and anti-dyskinetic in models
Safetyrisks and cautions, not medical advice
Human safety data are limited but reassuring at the doses studied. In the 13-week type 2 diabetes trial, 5 mg twice daily was well tolerated with no signal of serious adverse effects, and unlike the withdrawn CB1 inverse agonist rimonabant, THCV does not appear to carry the same nausea and mood-disturbance liability, since it behaves as a neutral CB1 antagonist rather than an inverse agonist. Practical caveats apply: most evidence is preclinical or from small studies, long-term safety is uncharacterised, and product quality varies widely because THCV is a minor cannabinoid that is often synthesised, converted or concentrated.
Its dose-dependent switch to CB1 agonism means high doses could in principle produce THC-like central effects. People who are pregnant or breastfeeding, those with cardiovascular or psychiatric conditions, and anyone taking glucose-lowering medication should be cautious, as appetite suppression and glycaemic effects could compound other treatments. Legal status is jurisdiction-dependent and should be verified before use.
History
THCV was first isolated and characterised from cannabis in the early 1970s as one of a family of propyl (varinic) cannabinoids, but for decades it remained a pharmacological curiosity overshadowed by THC. Sustained interest began in the 2000s, driven largely by the Aberdeen laboratory of Roger Pertwee and by GW Pharmaceuticals (later Jazz Pharmaceuticals), whose researchers systematically mapped its cannabinoid-receptor pharmacology and advanced it as a chemically defined botanical drug candidate. Pertwee's influential 2007 review formalised the now-standard description of THCV as a CB1 antagonist and CB2 partial agonist, and subsequent GW-associated work extended this to metabolic, neurological and psychiatric models, culminating in the University of Nottingham and GW type 2 diabetes trial reported in 2016 [1][6].
Reputation
THCV is popularly marketed as diet weed or the sports car of cannabinoids, a stimulating, appetite-curbing alternative to THC that promises weight loss, sharper energy and steadier blood sugar. There is a real scientific kernel behind the hype: its CB1 antagonism genuinely suppresses appetite in animals, its metabolic effects are supported by consistent preclinical data, and a single small human trial did show improved fasting glucose and beta-cell function. That said, the marketing runs well ahead of the evidence; the human data rest largely on one pilot study, most claims about energy, focus and fat loss in people are extrapolated from rodents, and product potency and purity are inconsistent. THCV is a promising, mechanistically distinctive cannabinoid, but it is not yet a proven therapeutic.
Subjective profileweighing the evidence above
Worth trying if you want a cannabinoid that suppresses appetite instead of driving it; 5 mg twice daily is the dose with an actual 13-week trial behind it, and it was well tolerated there. Keep it low, since higher amounts flip it toward THC-like effects, and buy carefully, because a minor cannabinoid means wildly variable product quality.
Resources
This entry is here for reference.
Research
- 2008first citedThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocan…
- 2016controlled trialEfficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters…
- 2025most recentTetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (…
- 1.The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
- 2.Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
- 3.Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
- 4.Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
- 5.Tetrahydrocannabivarin (THCV) Dose Dependently Blocks or Substitutes for Tetrahydrocannabinol (THC) in a Drug Discrimination Task in Rats.
- 6.Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.
- 7.The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
- 8.Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.
- 9.The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.
- 10.Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats.
- 11.Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
- 12.Beneficial effects of the phytocannabinoid Δ(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.
12 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Does THCV get you high?
At the low doses associated with its metabolic and appetite effects, THCV acts as a CB1 antagonist and is essentially non-intoxicating. At higher doses it can switch to activating CB1 and may produce milder, THC-like central effects, so intoxication is dose-dependent rather than a fixed property.
Why is THCV called diet weed?
Because it does the opposite of THC on appetite. By blocking the CB1 receptor at low doses it suppresses food intake instead of causing the munchies, and in animals it also raised energy expenditure, which is where the weight-management reputation comes from.
Is there real evidence it helps blood sugar?
Yes, though limited. In a randomised, placebo-controlled pilot study in type 2 diabetes, 5 mg twice-daily THCV significantly lowered fasting glucose and improved pancreatic beta-cell function, supporting earlier findings in obese mice. It is promising but not yet an established treatment.
How is THCV different from THC?
Chemically, THCV has a shorter three-carbon side chain versus THC's five-carbon chain. Pharmacologically that changes everything: THC is a CB1 agonist that stimulates appetite, while low-dose THCV is a CB1 antagonist that suppresses it, and THCV is also a stronger CB2 partial agonist.
Limitations of the evidence
- Human safety and efficacy rest largely on a single small pilot trial, so long-term effects are unknown.
Adverse effects
- At high doses it can shift to CB1 agonism and produce THC-like central effects.
- May lower blood glucose and appetite in ways that compound diabetes medication or unwanted weight loss.
Notes and cautions
- Product potency and purity are inconsistent because THCV is a minor, often converted or concentrated cannabinoid.